Methotrexate associated to lipid core nanoparticles improves cardiac allograft vasculopathy and the inflammatory profile in a rabbit heart graft model
AUTOR(ES)
Fiorelli, A.I., Lourenço-Filho, D.D., Tavares, E.R., Carvalho, P.O., Marques, A.F., Gutierrez, P.S., Maranhão, R.C., Stolf, N.A.G.
FONTE
Braz J Med Biol Res
DATA DE PUBLICAÇÃO
17/08/2017
RESUMO
Coronary allograft vasculopathy is an inflammatory-proliferative process that compromises the long-term success of heart transplantation and has no effective treatment. A lipid nanoemulsion (LDE) can carry chemotherapeutic agents in the circulation and concentrates them in the heart graft. The aim of the study was to investigate the effects of methotrexate (MTX) associated to LDE. Rabbits fed a 0.5% cholesterol diet and submitted to heterotopic heart transplantation were treated with cyclosporine A (10 mg·kg–1·day–1 orally) and allocated to treatment with intravenous LDE-MTX (4 mg/kg, weekly, n=10) or with weekly intravenous saline solution (control group, n=10), beginning on the day of surgery. Animals were euthanized 6 weeks later. Compared to controls, grafts of LDE-MTX treated rabbits showed 20% reduction of coronary stenosis, with a four-fold increase in vessel lumen and 80% reduction of macrophage staining in grafts. Necrosis was attenuated by LDE-MTX. Native hearts of both LDE-MTX and Control groups were apparently normal. Gene expression of lipoprotein receptors was significantly greater in grafts compared to native hearts. In LDE-MTX group, gene expression of the pro-inflammatory factors tumor necrosis factor-α, monocyte chemoattractant protein-1, interleukin-18, vascular cell adhesion molecule-1, and matrix metalloproteinase-12 was strongly diminished whereas expression of anti-inflammatory interleukin-10 increased. LDE-MTX promoted improvement of the cardiac allograft vasculopathy and diminished inflammation in heart grafts.
Documentos Relacionados
- Aerobic exercise improves the inflammatory profile correlated with cardiac remodeling and function in chronic heart failure rats
- New developments in the diagnosis and management of cardiac allograft vasculopathy.
- Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy
- What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
- Analysis of the risk factors for allograft vasculopathy in asymptomatic patients after cardiac transplantation